To investigate whether inhibition of PIR enhances the therapeutic effect of cetuximab (EGFR mAb, a standard approach in clinical CRC treatment) on CRC, we created CT26 cell‐based allograft model in BALB/c mice. This evidence concerns the gene PIR and colorectal carcinoma.